Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Acetyl-L-carnitine; ALC; Alcar; Branigen; L-acetylcarnitine; Nicetile; RO 447190; ST 200; ST 211HCl; Zibren

Latest Information Update: 16 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer Dong-A ST; GlaxoSmithKline; sigma-tau SpA; Tanabe Seiyaku
  • Class Antidementias; Neuroprotectants; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Carnitine acetyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia; Diabetic neuropathies; Peripheral nervous system diseases
  • Discontinued Diabetic complications; Fatigue

Most Recent Events

  • 02 Nov 2016 Launched for Alzheimer's disease in South Korea (PO) before November 2016
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 20 Sep 2007 Levacecarnine licensed to Lee's Pharmaceutical in China and Hong Kong
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top